Lifeboat Foundation

Bethesda, Md., Thurs., May 6, 2010 — Researchers have produced the first whole genome sequence of the 3 billion letters in the Neanderthal genome, and the initial analysis suggests that up to 2 percent of the DNA in the genome of present-day humans outside of Africa originated in Neanderthals or in Neanderthals’ ancestors.

The international research team, which includes researchers from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, reports its findings in the May 7, 2010, issue of Science.

The current fossil record suggests that Neanderthals, or Homo neanderthalensis, diverged from the primate line that led to present-day humans, or Homo sapiens, some 400,000 years ago in Africa. Neanderthals migrated north into Eurasia, where they became a geographically isolated group that evolved independently from the line that became modern humans in Africa. They lived in Europe and western Asia, as far east as southern Siberia and as far south as the Middle East.

Exercise boosts your brain, but a walk on the wild side is what you need to keep your hippocampus happy.

Giacomo Grasselli — a senior Italian government health official who is coordinating the network of intensive care units in Lombardy — explains the “critical” situation in Italy, brought about by the Covid-19 outbreak (Subscribe: https://bit.ly/C4_News_Subscribe)

——

Continue reading “Coronavirus ‘worse than a bomb’ on Italy, says doctor coordinating response” »

Coronavirus Spread Spurs Debate Over Which Health Workers Need To Be Quarantined : Shots — Health News Should “potential exposure” by a health worker to someone with coronavirus be enough to send that worker home for two weeks of self-quarantine? Health systems have begun debating relative risks.

Let’s say it was possible to buy your health by the day. How much would you be willing to pay for each year of perfect health? What if you could buy years of health for your loved ones, too? At what price point would you draw the line?

This sort of difficult calculus, on a much larger and chronologically longer scale, underpins many decisions we make in medicine — not just decisions that we make as patients, but also the decisions that are made for us by employers, health insurance funders and policymakers. We don’t have the resources to pursue every possible treatment, to research every possible breakthrough, so how do we allocate the resources available? It turns out that there is an entire field of healthcare economics devoted to understanding the costs and benefits of conventional medicine, and to navigating the trade-offs between more expense and better healthcare.

Continue reading “Econogenomics: The Economics of Genomic Testing for Health” »

The National Institutes of Health is testing the antiviral drug remdesivir, which is also being studied in patients in China. Running trials during epidemics is tricky, but scientists learned a lot about how to conduct them during recent Ebola outbreaks.

But using porous TCP to print bones does have some drawbacks. Its compressive strength is much lower than that of some human load-bearing bones, such as our thighbones. Compressive strength would rise over time, but it could be years before it would match pre-operation strength levels.

3D Printing Bones for Mars?

Several other groups are working on similar approaches. At NYU School of Medicine and NYU Langone Health, scientists have been developing 3D printed scaffold implants that could help patient groups such as children with skull deform ities. Early research results show that up to 77 percent of the bone scaffolding had been absorbed and replaced by natural bone 6 months after surgery, and that the newly-grown bone was just as strong as the original.

Avigan was developed as a flu medicine and also has been used for Ebola virus disease (EVD) treatment. EVD, which causes fatal hemorrhagic fever, resulted in more than 11,300 deaths in the West Africa region between 2014 and 2016. There is currently another outbreak in the Democratic Republic of Congo that has seen more than 2,000 fatalities to date.

HONG KONG – Fujifilm Holdings Corp. stock (TYO:4901) jumped 8.8% to ¥5,890 (US$53.48) on Feb. 25, as Japan considers using Avigan (favipiravir), an anti-influenza medication developed by the company’s Toyama Chemical Co. Ltd., to treat COVID-19. The share price ended the day at ¥5,567, for a gain of 2.83%.

The medication attracted market attention when Minister of Health, Labor and Welfare Katsunobu Kato said on Feb. 22 that the country is planning to test Avigan against COVID-19. “We hear from foreign countries that some drugs among those that have been used against influenza may be useful,” Kato said.

Continue reading “Fujifilm stock rises as Japan considers Avigan for COVID-19 treatment” »

Would you want to know if you’re at risk of Alzheimer’s disease, for example?

The integration of sequencing into health care doesn’t fit very well in the model of how medicine is practiced today, but is well aligned with the future vision of health care that so many of us have — a vision that focuses upon prediction and prevention.

Continue reading “Genome Sequencing for Healthy People: Is it Time?” »